Microbot Medical mentioned its objective is to take away obstacles to optimum care with the LIBERTY endovascular robotic system. | Supply: Microbot Medical
Microbot Medical Inc., the developer of the LIBERTY Endovascular Robotic System, at the moment mentioned the Japanese Patent Workplace has granted the corporate its first patent in Japan. The patent covers the core LIBERTY expertise, corresponding to a compact robotic gadget for driving and manipulating the motion of at the very least one elongate surgical instrument.
As well as, the Hingham, Mass.-based firm has acquired patents within the U.S., China, and Israel over the previous 90 days. It additionally earned 510(ok) clearance from the U.S. Meals and Drug Administration (FDA) for LIBERTY in September.
“Our preliminary focus is on the U.S. market. Nonetheless, sure markets, corresponding to Japan, signify enticing and strategically vital markets for the LIBERTY System,” mentioned Harel Gadot, chairman, president, and CEO of Microbot. “Constructing on our current FDA clearance of LIBERTY, we’re evaluating alternatives to develop into different international markets which have historically taken FDA clearance into consideration to doubtlessly expedite native approval and adoption.”
Based in 2010, Microbot Medical is concentrated on reworking endovascular procedures by means of superior robotic expertise.
LIBERTY guarantees exact, distant operation
LIBERTY is an endovascular robotic system for interventional physicians and hospitals looking for to enhance procedural precision, security, and effectivity, in keeping with Microbot Medical. In contrast to conventional handbook methods, it provides a single-use, compact design that allows managed distant operation, the corporate claimed.
The surgical robotic can be utilized in neurovascular, cardiovascular, and peripheral vascular procedures. Microbot added that LIBERTY might decrease process prices and enhance the general high quality of care.
In August, Microbot introduced a brand new patent masking a modular robotic surgical system. The system features a base and a number of tool-receiver items organized as separate items. These items are independently and interchangeably attachable to the bottom. The corporate mentioned the patent might permit it to adapt Liberty for a wider vary of endovascular procedures.
Microbot Medical to lift $92M from inventory sale
Microbot Medical final month mentioned buyers agreed to train excellent most popular funding choices, which might generate as much as $92.2 million in gross proceeds. It intends to make use of the proceeds to help growth, commercialization, and regulatory work for its LIBERTY system.
The corporate additionally plans to pursue potential acquisitions, develop purposes of its mental property, and use the funding for working capital and common company functions. Microbot mentioned the newest developments have accelerated its industrial launch plans.
Surgical robotics can be on the agenda at RoboBusiness 2025, which takes place Oct. 15 and 16 in Santa Clara, Calif. Iman Jeddi, Ph.D. and senior vp and common supervisor of Intuitive Surgical’s multiport platform, will provide a glance contained in the redesign and launch of the da Vinci 5, the firm‘s next-generation surgical robotics system.
